Velmanase alfa approved for treatment of non-central nervous system manifestations of alpha-mannosidosis: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)

Documenti analoghi

• Velmanase alfa approved for treatment of non-central nervous system manifestations of alpha-mannosidosis: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
  di: Julie M. Lander, et al.
  Pubblicazione: (2024-01-01)
• Relationship between MAN2B1 genotype/subcellular localization subgroups, antidrug antibody detection, and long‐term velmanase alfa treatment outcomes in patients with alpha‐mannosidosis
  di: Line Gutte Borgwardt, et al.
  Pubblicazione: (2023-03-01)
• Alfa-mannosidosis: Frequent Symptoms in Rare Patient
  di: Nato D. Vashakmadze, et al.
  Pubblicazione: (2023-01-01)
• Response to the Letter to the Editor concerning ‘Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis’
  di: Ivana Stević, et al.
  Pubblicazione: (2024-12-01)
• Letter to the Editor concerning ‘cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis’
  di: A. L. Stevenson, et al.
  Pubblicazione: (2024-12-01)